CA3143278A1 — Tyrosine kinase inhibitor conjugates
Assigned to Ascendis Pharma Oncology Division AS · Expires 2020-12-24 · 5y expired
What this patent protects
The present invention relates to a tyrosine kinase inhibitor ("TKI") conjugate or a pharmaceutically acceptable salt thereof, wherein said conjugate comprises a plurality of TKI moieties -D covalently conjugated via at least one moiety -L1 -L2 - to a polymeric moiety Z, w…
USPTO Abstract
The present invention relates to a tyrosine kinase inhibitor ("TKI") conjugate or a pharmaceutically acceptable salt thereof, wherein said conjugate comprises a plurality of TKI moieties -D covalently conjugated via at least one moiety -L1 -L2 - to a polymeric moiety Z, wherein -L - is covalently and reversibly conjugated to -D and -L2 - is covalently conjugated to Z and wherein -L1- is a linker moiety and -L2- is a chemical bond or a spacer moiety; and to related aspects.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.